Scientific article
English

Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08)

Published in

European urology, vol. 64, no. 1, p. 150-158

Publication date

2013

Abstract

The phosphatase and tensin homolog (PTEN) tumor suppressor gene is deregulated in many advanced prostate cancers, leading to activation of the phosphatidylinositol 3-kinase (PI3K)-Akt-mammalian target of rapamycin (mTOR) pathway and thus increased cell survival.

Citation (ISO format)

TEMPLETON, Arnoud J et al. Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08). In: European urology, 2013, vol. 64, n° 1, p. 150–158. doi: 10.1016/j.eururo.2013.03.040

Main files (1)

Article (Published version)

Identifiers

Journal ISSN

0302-2838
624views
0downloads

Technical informations

Creation

12/12/2013 22:40:00

First validation

12/12/2013 22:40:00

Update

14/03/2023 20:54:35

Status update

14/03/2023 20:54:34

Last indexation

30/10/2024 16:05:02
All rights reserved by Archive ouverte UNIGE and the University of Geneva
OpenAIRE Indexed & Validated